November 2012

Date: 
November, 2012
Deck: 
Max Wallace, CEO of Accelerate Brain Cancer Cure, provides perspective on the latest Avastin trial results by Genentech.

Dear Friends,

I want to share with you the latest news on Avastin® (bevacizumab), a treatment for patients with glioblastoma, the most common and aggressive form of brain cancer. 

This fall, ABC2 supporters had the unique opportunity to learn first-hand about the latest advances in brain tumor research at a series of ABC2 Science Salon events across the country. 

Deck: 
A blog post from Max Wallace, CEO of Accelerate Brain Cancer Cure.

Our Annual Scientific Gathering is central to identifying, developing and funding research projects for the new year.

Share |

Join us in our fight for a cure!

Twitter